Today, the SP closed 2.2% up. Keep the faith.
7/6/21 Recce Clinical Pipeline Update
Murdoch Children’s Research Institute - Helicobacter pylori (H. pylori)
The Company’s oral compound against Helicobacter pylori (H. pylori) infections, RECCE 435, continues to show significant efficacy in multiple H. pylori strains in preclinical studies in-vitro and in-vivo (mouse). The next stage of the H. pylori program is underway, with results expected July 2021
Ann: Multiple Patients Dosed in Topical Phase I/II Clinical Trial, page-50
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $83.62M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 32.0¢ | 29.0¢ | $25.51K | 83.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21189 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 7696 | 4 |
View Market Depth
| Last trade - 14.16pm 25/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |